Tahir Amin discusses his new book on how to change the pharmaceutical industry for the better.

In a letter, Sen. Maggie Hassan cited ICIJ's Cancer Calculus investigation and expressed concerns that the pharma giant is boosting profits at the expense of patients.

“Just because a company invests does not mean it has invented anything novel,” Tahir Amin and Rohit Malpani write in this excerpt from “Pharma Monopoly.”

Over the next year, countries that are home to 40% of the world’s population are set to get access to Ozempic and Wegovy generics that could cost as little as $15 a month.

Over the next year, countries that are home to 40% of the world’s population are set to get access to Ozempic and Wegovy generics that could cost as little as $15 a month.

The findings raise questions about whether the administration’s “most favored nation” deals are having a meaningful impact on patients.

How Merck keeps the price of its lifesaving cancer drug, Keytruda, sky-high, locking out patients and squeezing health care systems worldwide.

Le Keytruda du géant étatsunien Merck Sharp & Dohme (MSD) représente un réel espoir pour les malades du cancer et les oncologues. Il est aussi le cauchemar des assureurs et des budgets de santé publiq...

Keytruda, manufactured by the US pharmaceutical giant Merck Sharp & Dohme (MSD), offers genuine hope for cancer patients and oncologists alike. However, it’s also a nightmare for insurers and public h...

How Merck keeps the price of its blockbuster cancer drug sky-high, shutting out patients and straining health care systems around the world.

Explore the U.S. patents Merck deploys to stymie competition and keep revenues for its blockbuster cancer drug flowing as long as possible.

Merck built a wall of patents that keeps a cancer drug's price – and its profits – high. Hospitals often add to the cost for American patients.

High prescription drug prices in the United States are often explained as an unavoidable consequence of investment in biomedical progress. Yet across therapeutic areas, delayed competition more often ...

As politicians prepare their pitches for the midterm elections, a survey finds that about 1 in 3 Americans are “very worried” about health care costs.

The Trump administration released the next 15 drugs subject to Medicare price negotiation, including for the first time treatments administered in doctor offices.

In the wake of U.S. Food and Drug Administration approvals for GLP-1 weight-loss drugs, surging public demand and massive profits have inspired a broad range of drugmaker litigation against competitor...

Despite some hard-fought victories in the fight for patent reform, our year-in-review newsletter must focus on something deeply troubling.

A new national survey reveals overwhelming bipartisan support for overhauling the patent system to address soaring prescription drug costs in the United